Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer's disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on…mehr
Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer's disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on gut tryptamine in domestic and agricultural animals is included. The book closes with case studies involving FDG-PET imaging in the context of tryptamine-treated mouse models and Alzheimer's disease patients. This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences.
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley's research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending.
Inhaltsangabe
1. Introduction 2. Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability 3. Mutagenicity and genotoxicity of naturally occurring tryptamines and their principle metabolites 4. Abundant urinary tryptamine as indicator of UTI and nosocomial infections 5. Proteus mirabilis, diseases and tryptamine 6. Microbial tryptophan metabolites in cancer and leishmaniasis 7. The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases 8. Retinitis Pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism and gut microbiome 9. The tRNA aminoacylation interference in diseases 10. Tryptamine interfere with Cytochrome P450 11. Discovery of ADAS and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions 12. Tryptamine, ADAS and microbiome in Parkinson’s disease 13. Gut microbial ADAS and tryptamine in domestic and agricultural animals 14. Tryptamine, stem cell/progenitor protein biosynthesis and aminoacyl-tRNA biosynthesis 15. Tryptamine metabolite indole-3-acetic acid (IAA) in neurodegenerative diseases and other conditions 16. FDG-PET: tryptamine-treated mouse model and Alzheimer’s disease patients. Conceptual evolution of microbiota tryptamine role in human diseases 17. Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance 18. Conclusions
1. Introduction 2. Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability 3. Mutagenicity and genotoxicity of naturally occurring tryptamines and their principle metabolites 4. Abundant urinary tryptamine as indicator of UTI and nosocomial infections 5. Proteus mirabilis, diseases and tryptamine 6. Microbial tryptophan metabolites in cancer and leishmaniasis 7. The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases 8. Retinitis Pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism and gut microbiome 9. The tRNA aminoacylation interference in diseases 10. Tryptamine interfere with Cytochrome P450 11. Discovery of ADAS and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions 12. Tryptamine, ADAS and microbiome in Parkinson’s disease 13. Gut microbial ADAS and tryptamine in domestic and agricultural animals 14. Tryptamine, stem cell/progenitor protein biosynthesis and aminoacyl-tRNA biosynthesis 15. Tryptamine metabolite indole-3-acetic acid (IAA) in neurodegenerative diseases and other conditions 16. FDG-PET: tryptamine-treated mouse model and Alzheimer’s disease patients. Conceptual evolution of microbiota tryptamine role in human diseases 17. Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance 18. Conclusions
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
